Want to see IN:PGHL full AI Analyst Report?
PGHL Stock Chart & Stats
₹5751.70
-₹54.70(-1.07%)
At close: 4:00 PM EST
₹5751.70
-₹54.70(-1.07%)
Day’s Range― - ―
52-Week Range₹4,699.70 - ₹6,955.00
Previous CloseN/A
Volume2.65K
Average Volume (3M)310.00
Market Cap
₹114.17B
Enterprise Value₹101.96K
Total Cash (Recent Filing)₹2.86B
Total Debt (Recent Filing)₹95.50M
Price to Earnings (P/E)34.8
Beta0.49
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.28%
Share Statistics
EPS (TTM)184.83
Shares Outstanding16,599,382
10 Day Avg. Volume340
30 Day Avg. Volume310
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)15.22
Price to Sales (P/S)5.67
P/FCF Ratio24.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)215.9
Revenue Forecast (FY)₹15.00B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and ample equity backing reduce financial risk and preserve strategic optionality. A conservative capital structure supports sustained investment in distribution and brand-building, makes the company resilient to demand swings, and lowers refinancing pressure over months.
High Profitability And MarginsConsistently strong gross and net margins indicate pricing power and efficient cost structure in the OTC health segment. Durable margins support reinvestment in marketing and R&D, fund shareholder returns, and help absorb input-cost swings, underpinning multi-quarter earnings resilience.
Improving Free Cash FlowA material FCF rebound improves internal funding for growth, working capital and dividends without adding leverage. Strong cash generation enhances financial flexibility for marketing, supply-chain investment and potential partnerships, strengthening the firm's ability to execute strategy over months.
Bears Say
Revenue Volatility / 2024 DipA prior revenue decline signals vulnerability in demand or channel execution; inconsistent top-line growth complicates multi-quarter planning for marketing and distribution scale. If not addressed, revenue volatility can slow sustainable market-share gains in a competitive OTC space.
Uneven Cash ConversionHistorical variability in converting earnings to operating cash and volatile FCF raises uncertainty about recurring cash available for investment or payouts. Persistent conversion swings could limit durable reinvestment capacity and make financing timing more sensitive over months.
Shrinking Equity And Assets Vs 2023A reduction in equity and total assets versus the prior year is a structural watch item: it may signal reduced scale, capital returns, or balance-sheet adjustments that could constrain growth capacity. Over several quarters this may limit investment or operational scale-up.
Procter & Gamble Health Ltd. News
PGHL FAQ
What was Procter & Gamble Health Ltd.’s price range in the past 12 months?
Procter & Gamble Health Ltd. lowest stock price was ₹4699.70 and its highest was ₹6955.00 in the past 12 months.
What is Procter & Gamble Health Ltd.’s market cap?
Procter & Gamble Health Ltd.’s market cap is ₹114.17B.
When is Procter & Gamble Health Ltd.’s upcoming earnings report date?
Procter & Gamble Health Ltd.’s upcoming earnings report date is Aug 06, 2026 which is in 20 days.
How were Procter & Gamble Health Ltd.’s earnings last quarter?
Procter & Gamble Health Ltd. released its earnings results on May 26, 2026. The company reported ₹57 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Procter & Gamble Health Ltd. overvalued?
According to Wall Street analysts Procter & Gamble Health Ltd.’s price is currently Overvalued.
Does Procter & Gamble Health Ltd. pay dividends?
Procter & Gamble Health Ltd. pays a Semiannually dividend of ₹45 which represents an annual dividend yield of 3.28%. See more information on Procter & Gamble Health Ltd. dividends here
What is Procter & Gamble Health Ltd.’s EPS estimate?
Procter & Gamble Health Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Procter & Gamble Health Ltd. have?
Procter & Gamble Health Ltd. has 16,599,382 shares outstanding.
What happened to Procter & Gamble Health Ltd.’s price movement after its last earnings report?
Procter & Gamble Health Ltd. reported an EPS of ₹57 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.219%.
Which hedge fund is a major shareholder of Procter & Gamble Health Ltd.?
Currently, no hedge funds are holding shares in IN:PGHL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Procter & Gamble Health Ltd.
Procter & Gamble Health Limited is an Indian entity focused on the production and distribution of pharmaceutical products and chemicals. Its extensive product portfolio includes a variety of over-the-counter (OTC) medications, as well as vitamins, minerals, and dietary supplements. The company's offerings are available under recognized brand names such as Polybion, Neurobion, Evion, Nasivion, Livogen, and Seven Seas. In addition to its domestic operations, Procter & Gamble Health Limited also exports its pharmaceutical goods to several international markets, including Sri Lanka, Nepal, Myanmar, and Maldives. Established in 1967, the company originally operated as Merck Limited, rebranding to Procter & Gamble Health Limited in May 2019. It is headquartered in Mumbai, India, and functions as a subsidiary of Procter & Gamble Overseas India B.V.
Technical Analysis
Amrutanjan Health Care Limited
―
Aurobindo Pharma Ltd
―
Glenmark Pharmaceuticals Limited
―
Mankind Pharma Ltd.
―
Zydus Lifesciences Limited
―